000 04318nam a2200433 i 4500
001 00012160
003 WSP
005 20260416153409.0
007 cr cnu|||unuuu
008 210408s2021 si ob 001 0 eng
040 _a WSPC
_b eng
_e rda
_c WSPC
010 _z 2020057455
020 _a9789811232312
_q(ebook)
020 _z9789811232305
_q(hardback)
050 0 4 _aRS420
_b.F47 2021
072 7 _aSCI
_x010000
_2bisacsh
072 7 _aTEC
_x059000
_2bisacsh
072 7 _aCOM
_x004000
_2bisacsh
082 0 4 _a615.1/9
_223
100 1 _aFernández, Ariel,
_d1957-
_eauthor.
245 1 0 _aArtificial intelligence platform for molecular targeted therapy :
_ba translational science approach /
_cby Ariel Fernández, Daruma Institute, Argentina & AF Innovation, USA & CONICET-National Research Council, Argentina.
264 1 _aSingapore :
_bWorld Scientific,
_c2021.
300 _a1 online resource (xviii, 450 pages)
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aForeword -- About the author -- Preface -- Propaedeutic to artificial intelligence -- Epistructural biology : a conceptual and representational framework for AI-based drug design -- Artificial intelligence constructs in vivo reality to expedite protein folding -- Epistructural meta-analysis of functional genomics repositories: Towards an ai platform to infer amyloidogenic propensity -- Molecular evolution from the perspective of epistructural biology -- Epistructural biochemistry -- Epistructural drug design : next-generation targeted therapeutics -- Anticancer treatment synergizing targeted therapies with immune responses -- Epistructurally engineered cancer susceptibility to checkpoint immunotherapy and the ai-empowered steering of cancer evolution towards extinction -- AI-empowered molecular dynamics -- Artificial intelligence guides drug design in the absence of information on target structure and regulation and unravels the origin of cooperativity -- Artificial intelligence teaches drugs to target proteins by solving the drug-induced folding problem -- Epilogue : AI constructs its own physics -- Appendix 1 : code for dehydron identification -- Index.
538 _aMode of access: World Wide Web.
538 _aSystem requirements: Adobe Acrobat Reader.
520 _a"In the era of big biomedical data, there are many ways in which artificial intelligence (AI) is likely to broaden the technological base of the pharmaceutical industry. Cheminformatic applications of AI involving the parsing of chemical space are already being implemented to infer compound properties and activity. By contrast, dynamic aspects of the design of drug/target interfaces have received little attention due to the inherent difficulties in dealing with physical phenomena that often do not conform to simplifying views. This book focuses precisely on dynamic drug/target interfaces and argues that the true game change in pharmaceutical discovery will come as AI is enabled to solve core problems in molecular biophysics that are intimately related to rational drug design and drug discovery. Here are a few examples to convey the flavor of our quest: How do we therapeutically impair a dysfunctional protein with unknown structure or regulation but known to be a culprit of disease? In regards to SARS-CoV-2, what is the structural impact of a dominant mutation?, how does the structure change translate into a fitness advantage?, what new therapeutic opportunity arises? How do we extend molecular dynamics simulations to realistic timescales, to capture the rare events associated with drug targeting in vivo? How do we control specificity in drug design to selectively remove side effects? This is the type of problems, directly related to the understanding of drug/target interfaces, that the book squarely addresses by leveraging a comprehensive AI-empowered approach"--Publisher's website.
504 _aIncludes bibliographical references and index.
650 0 _aDrugs
_xDesign.
650 0 _aDrug development.
650 0 _aArtificial intelligence.
_94
650 0 _aMolecular dynamics.
655 0 _aElectronic books.
856 4 0 _uhttps://www.worldscientific.com/worldscibooks/10.1142/12160#t=toc
942 _cE-BOOK
999 _c49738
_d49738